VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CRVL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CRVLCorVel Corporation
$62.99$3.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCRVLFinancials

CorVel Corporation (CRVL) Financials

30Y historyFree accessUpdated daily

Revenue growth remains stable at 7.03% year-over-year as of 2026Q4, while underwriting efficiency has improved significantly with the combined ratio tightening to 84.0% from 89.1% in 2024Q4.

CRVL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00Mar'99Mar'98Mar'97
Revenue958.53M895.59M795.31M718.56M646.23M552.64M592.23M595.74M558.35M518.69M503.58M492.63M478.82M429.31M412.67M380.67M337.97M310.08M301.89M274.58M266.5M291M305.28M282.78M235.91M209.55M186.76M165.46M141.71M121.7M
Revenue Growth %7.03%12.61%10.68%11.19%16.93%-6.68%-0.59%6.7%7.65%3%2.22%2.88%11.53%4.03%8.41%12.63%9%2.71%9.95%3.03%-8.42%-4.68%7.96%19.86%12.58%12.2%12.88%16.76%16.44%11.55%
Medical Costs & Claims725.66M685.86M623.62M560.3M494.12M429.02M466.3M470.93M451.1M413.89M399.04M392.66M370.33M337.65M318.83M284.1M252.43M236.33M223.83M208.75M221.06M246.34M253.85M230.95M193.22M172.01M145.75M129.8M110.3M95.1M
Medical Cost Ratio %75.71%76.58%78.41%77.98%76.46%77.63%78.74%79.05%80.79%79.8%79.24%79.71%77.34%78.65%77.26%74.63%74.69%76.22%74.14%76.02%82.95%84.65%83.15%81.67%81.91%82.08%78.04%78.45%77.84%78.14%
Gross Profit232.86M209.73M171.69M158.26M152.11M123.62M125.92M124.81M107.25M104.79M104.54M99.97M108.48M91.66M93.84M96.57M85.54M73.74M78.06M65.83M45.44M44.66M51.43M51.83M42.69M37.54M41.02M35.66M31.41M26.6M
Gross Margin %24.29%23.42%21.59%22.02%23.54%22.37%21.26%20.95%19.21%20.2%20.76%20.29%22.66%21.35%22.74%25.37%25.31%23.78%25.86%23.98%17.05%15.35%16.85%18.33%18.09%17.92%21.96%21.55%22.16%21.86%
Gross Profit Growth %11.03%22.15%8.49%4.04%23.05%-1.82%0.89%16.37%2.35%0.24%4.58%-7.85%18.35%-2.33%-2.82%12.9%16%-5.54%18.58%44.87%1.76%-13.17%-0.76%21.42%13.7%-8.47%15.04%13.52%18.08%14.66%
Operating Expenses89.73M88.9M76.59M73.7M67.6M64.45M65.21M63.3M59.35M57.24M58.48M54.41M51.97M47.77M50.41M59.17M42.06M42.13M39.72M35.38M29.59M28.14M26.07M25.08M18.78M16.39M21.72M18.9M16.3M12.8M
OpEx / Revenue %9.36%9.93%9.63%10.26%10.46%11.66%11.01%10.62%10.63%11.04%11.61%11.04%10.85%11.13%12.21%15.54%12.44%13.59%13.16%12.89%11.1%9.67%8.54%8.87%7.96%7.82%11.63%11.42%11.5%10.52%
Depreciation & Amortization029.54M26.25M25.12M23.92M23.44M22.52M22.98M21.77M20.97M19.95M18M16.41M15.74M14.72M12.25M11.99M11.78M11.77M10.12M10.94M11.09M9.96M9.34M8.41M6.76M6.96M6.3M5.3M4.2M
Combined Ratio %85.07%86.51%88.04%88.23%86.92%89.29%89.75%89.67%91.42%90.83%90.85%90.75%88.2%89.78%89.47%90.17%87.13%89.81%87.3%88.91%94.05%94.32%91.69%90.54%89.87%89.9%89.66%89.87%89.34%88.66%
Operating Income143.13M120.82M95.1M84.55M84.51M59.17M60.71M61.51M47.9M47.55M46.06M45.56M56.51M43.9M43.44M37.4M43.48M31.61M38.34M30.45M15.85M16.52M25.37M26.75M23.9M21.16M19.3M16.76M15.11M13.8M
Operating Margin %14.93%13.49%11.96%11.77%13.08%10.71%10.25%10.33%8.58%9.17%9.15%9.25%11.8%10.22%10.53%9.83%12.87%10.19%12.7%11.09%5.95%5.68%8.31%9.46%10.13%10.1%10.34%10.13%10.66%11.34%
Operating Income Growth %18.46%27.05%12.47%0.05%42.82%-2.53%-1.3%28.41%0.74%3.23%1.09%-19.37%28.73%1.05%16.13%-13.98%37.57%-17.57%25.92%92.08%-4%-34.89%-5.17%11.9%12.99%9.59%15.19%10.91%9.49%14.05%
EBITDA143.13M150.36M121.35M109.67M108.43M82.61M83.23M84.5M69.68M68.52M66.01M63.56M72.92M59.63M58.16M49.65M55.47M43.39M50.11M40.57M26.79M27.6M35.32M36.09M32.32M27.91M26.27M23.06M20.41M18M
EBITDA Margin %14.93%16.79%15.26%15.26%16.78%14.95%14.05%14.18%12.48%13.21%13.11%12.9%15.23%13.89%14.09%13.04%16.41%13.99%16.6%14.78%10.05%9.48%11.57%12.76%13.7%13.32%14.06%13.94%14.4%14.79%
Interest Expense000000000000000000000000000000
Non-Operating Income000000000000000000000000000000
Pretax Income143.13M120.82M95.1M84.55M84.51M59.17M60.71M61.51M47.9M47.55M46.06M45.56M56.51M43.9M43.44M37.4M43.48M31.61M38.34M30.45M15.85M16.52M25.37M26.75M23.9M21.16M19.3M16.8M15.2M13.7M
Pretax Margin %14.93%13.49%11.96%11.77%13.08%10.71%10.25%10.33%8.58%9.17%9.15%9.25%11.8%10.22%10.53%9.83%12.87%10.19%12.7%11.09%5.95%5.68%8.31%9.46%10.13%10.1%10.34%10.15%10.73%11.26%
Income Tax32.79M25.66M18.85M18.19M18.1M12.82M13.33M14.81M12.21M18.07M17.54M16.97M22.11M17.16M16.89M12.74M17.39M12.33M14.96M11.88M6.1M6.36M9.35M10.16M9.08M7.93M7.34M6.4M5.7M5.2M
Effective Tax Rate %22.91%21.24%19.82%21.51%21.42%21.66%21.96%24.08%25.48%38%38.07%37.25%39.14%39.1%38.87%34.06%39.99%39.01%39.02%39%38.48%38.5%36.87%38%38%37.5%38%38.1%37.5%37.96%
Net Income110.34M95.17M76.25M66.36M66.41M46.36M47.38M46.7M35.7M29.48M28.52M28.59M34.39M26.73M26.55M24.66M26.1M19.28M23.38M18.58M9.75M10.16M16.01M16.58M14.82M13.22M11.97M10.4M9.5M8.5M
Net Margin %11.51%10.63%9.59%9.24%10.28%8.39%8%7.84%6.39%5.68%5.66%5.8%7.18%6.23%6.43%6.48%7.72%6.22%7.75%6.77%3.66%3.49%5.25%5.86%6.28%6.31%6.41%6.29%6.7%6.98%
Net Income Growth %15.95%24.8%14.9%-0.07%43.26%-2.16%1.44%30.84%21.09%3.34%-0.23%-16.87%28.66%0.67%7.66%-5.49%35.37%-17.56%25.88%90.46%-3.98%-36.57%-3.44%11.9%12.09%10.49%15.07%9.47%11.76%16.44%
EPS (Diluted)2.141.831.471.261.222.502.562.461.871.511.431.371.610.360.360.330.350.260.280.220.110.100.170.170.130.110.100.090.090.06
EPS Growth %16.94%24.49%16.67%3.28%-51.2%-2.34%4.06%31.55%23.84%5.59%4.38%-14.91%347.22%0%9.09%-5.71%34.62%-7.14%27.27%100%14.58%-43.53%0%30.77%18.18%11.11%4.54%9.99%43.5%17.65%
EPS (Basic)2.151.851.481.281.250.860.860.830.630.510.470.471.630.360.360.340.360.260.280.220.110.100.170.170.140.120.100.090.090.06
Diluted Shares Outstanding51.63M52.04M52.04M52.78M54.38M18.54M18.54M19.01M19.04M19.57M20M20.89M63.72M74.26M74.26M74.26M74.26M74.26M84.22M85.61M87.55M94.68M95.79M97.46M102.3M105.04M110.04M109.77M110.3M126.6M

Key Metrics

Growth RegimeStable
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Medical labor cost inflation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Steady Revenue Expansion Amidst Stability

As reported in recent financial statements, CorVel achieved a 7.03% year-over-year revenue growth in 2026Q4, reflecting a consistent ability to capture claims volume despite the inherent volatility of the U.S. workers' compensation market and shifting employment levels across the domestic landscape.

The company's revenue trajectory appears to be supported by a stable demand environment for claims management services. Investors should monitor whether this growth is driven by organic volume increases or if it is being bolstered by inflationary adjustments in medical billing charges.

Underwriting Efficiency Drives Margin Expansion

Based on the provided figures, the combined ratio improved to 84.0% in 2026Q4, demonstrating that CorVel's proprietary CareMC platform is effectively containing costs and enhancing underwriting profitability compared to the 89.1% ratio observed in 2024Q4, according to historical data.

The consistent downward trend in the combined ratio suggests that the company is successfully leveraging its technology stack to automate labor-intensive tasks. This improvement implies that CorVel may be achieving greater operating leverage as its software-driven solutions scale relative to its professional service headcount.

Operational Scale Through Technology Integration

According to the latest quarterly data, operating income reached $39.7M in 2026Q4, which indicates that the company is successfully managing its administrative overhead while scaling its core service offerings through the integration of advanced automation and proprietary software workflows.

The ability to expand operating margins while maintaining a lean cost structure suggests that CorVel's investment in its unified platform is yielding tangible efficiency gains. Analysts should investigate whether this margin expansion is sustainable or if it remains vulnerable to potential wage inflation in the clinical nursing sector.

Risks to Sustained Margin Performance

While the combined ratio has shown improvement, investors should monitor the potential for wage inflation to impact the Patient Management segment, as the company's reliance on specialized medical labor may create margin pressure that could offset gains from automated bill review processes.

The reliance on human-centric services like case management warrants further investigation into the company's ability to pass through rising labor costs to its clients. If the current inflationary environment persists, the company's profitability may face headwinds that are not currently reflected in the recent margin expansion.

CRVL — Frequently Asked Questions

Quick answers to the most common questions about buying CRVL stock.

What was CorVel Corporation's (CRVL) revenue in 2026?

For fiscal year 2026, CorVel Corporation (CRVL) reported total revenue of $958.5M. This represents a 687.6% increase compared to $121.7M in 1997.

Is CorVel Corporation (CRVL) profitable?

CorVel Corporation (CRVL) is profitable, generating $110.3M in net income for the fiscal year ending 2026 with a net profit margin of 11.5%.

What is CorVel Corporation's operating profit margin?

CorVel Corporation (CRVL) reported an operating income of $143.1M, resulting in an operating profit margin of 14.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is CorVel Corporation's gross profit and gross margin?

CorVel Corporation (CRVL) generated $232.9M in gross profit for the year, representing a gross profit margin of 24.3%. This demonstrates the company's core pricing power and production efficiency.